AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

Launched by COLUMBIA UNIVERSITY · Apr 24, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on helping Spanish-speaking Latinx patients who are undergoing treatment for breast or prostate cancer. The goal is to create educational materials that will better prepare these patients for their radiation therapy and help them make informed decisions about participating in cancer clinical trials. The study is currently looking for participants who are between the ages of 65 and 74 and who identify as Latinx, meaning they come from Mexican, Puerto Rican, Cuban, Dominican, or Central or South American backgrounds.

To be eligible for the trial, participants must be Spanish speakers currently receiving treatment for non-metastatic breast or prostate cancer. They should also have a confirmed diagnosis and a good performance status, which means they can carry out daily activities with minimal difficulty. Participants can expect to engage in educational sessions, and it's important that they have consultations with a certified interpreter to ensure clear communication. This study aims to provide valuable support to Latinx patients during their cancer treatment journey.

Gender

ALL

Eligibility criteria

• Pilot Phase Inclusion Criteria:
• • 1. Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry
• • 2. Currently undergoing treatment for breast or prostate cancer, or recently been treated
• Pilot Phase Exclusion Criteria:
• • 1. Patient with bilateral deafness and/or blindness
• • 2. Patient with psychosis and/or dementia
• Main Study Inclusion Criteria:
• • 1. Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry
• • 2. Patients with non-metastatic prostate or breast cancer
• • 3. Histopathologically proven diagnosis of prostate or breast cancer
• • 4. History and physical examination within 28 days prior to enrollment
• • 5. Karnofsky performance status 70 or greater
• • 6. For women of childbearing potential, pregnancy testing to be performed in accordance to institutional guidelines
• • 7. Plan to receive definitive, curative radiation. Patients planning to receive curative RT after upcoming adjuvant chemotherapy or induction hormonal therapy may enroll at reconsult "follow-up" visit.
• • 8. Consultation visit must be performed with a certified interpreter
• Main Study Exclusion Criteria:
• • 1. Patient with bilateral deafness and/or blindness
• • 2. Patient with psychosis and/or dementia
• • 3. Clinical or radiological evidence of metastatic disease
• • 4. Prior participation in cancer patient education trial
• • 5. Prior RT
• • 6. RT for sites other than breast or prostate